Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apoptosis, Autophagy, Mitophagy, Inflammation, and Necroptosis

Abstract: Cancer is the second leading cause of mortality worldwide. Conventional therapies, including surgery, radiation, and chemotherapy, have limited success because of secondary resistance. Therefore, safe, non-resistant, less toxic, and convenient drugs are urgently required. Natural products (NPs), primarily sourced from medicinal plants, are ideal for cancer treatment because of their low toxicity and high success. NPs cure cancer by regulating different pathways, such as PI3K/AKT/mTOR, ER stress, JNK, Wnt, STAT3, MAPKs, NF-kB, MEK-ERK, inflammation, oxidative stress, apoptosis, autophagy, mitophagy, and necroptosis. Among the NPs, steroid saponins, including polyphyllins (I, II, D, VI, and VII), have potent pharmacological, analgesic, and anticancer activities for the induction of cytotoxicity. Recent research has demonstrated that polyphyllins (PPs) possess potent effects against different cancers through apoptosis, autophagy, inflammation, and necroptosis. This review summarizes the available studies on PPs against cancer to provide a basis for future research.

Keywords: natural products, saponins, polyphyllins, apoptosis, autophagy, inflammation, necroptosis

Introduction
Cancer is the second leading cause of mortality worldwide. A WHO report shows that cancer causes more deaths in the world compared with stroke and coronary heart diseases. Factors that increase cancer incidence include overpopulation and aging. Global epidemiologic and demographic transition signals indicate that cancer will increase in the next decade, especially in countries with low or middle income. A recent report has estimated that 18.1 million new cancer cases excluding non-melanoma skin cancer (17.0 million cases) and 9.6 million cancer-related deaths excluding non-melanoma skin cancer (9.5 million cases) were recorded in 2018. In both genders combined, lung cancer (11.6% of total reported cases) was more common, followed closely by female breast (11.6%), prostate (7.1%), and colorectal (6.1%) cancers. Lung cancer was also the leading cause of death (18.4% of the total reported cases), followed by colorectal cancer (9.2%), stomach (8.2%), and liver (8.2%) cancers.

Available clinical treatment for cancer includes surgery, chemotherapy, and radiotherapy. Conventional therapies, including surgery, radiation, and chemotherapy, have limited success because of secondary resistance. Therefore, safe, non-resistant,
less toxic, and convenient drugs are urgently required. These NPs, primarily sourced from medicinal plants, are ideal for cancer treatment because of their low toxicity and high success. These NPs cure cancer by regulating different pathways, such as PI3K/AKT/mTOR, NF-κB, autophagy, MEK-ERK, inflammation, oxidative stress, and apoptosis.

*Paris* (Melanthiaceae) consists of 29 species, many of which are used as traditional herbal medicines and distributed in Eastern Asia and Europe. Among 29 species of *Paris*, 22 are found in China and its diversity center in China is South-west China. In China, extracts from *Paris* species are extensively used as herbal medicine. Paridis, the dry rhizome of *Paris*, is used as a main raw material in patent Chinese drugs, including “GongXue Ning,” “Jidesheng snake tablet,” and “Yunnan Baiyao”. For a thousand years, this herb has been used in traditional Chinese medicine for the treatment of various diseases, such as snakebite, parotitis, hemostasis, abscess, and fractures. Modern research explored its new pharmacological activities, including cytotoxic, hemolytic, antibiotic, spermicidal, styptovit analgesic, calming, immunoregulatory, antihelmintic, anti-inflammatory, and anticancer activities.

Photochemical research found several active ingredients in the dried rhizome of *Paris*, including flavonoids, endophytic fungi, fatty acid ester, and steroid saponins, such as Polyphyllin I (PPI), Polyphyllin II (PPII), Polyphyllin VI (PPVI), and Polyphyllin VII (PPVII). Modern research revealed that the PPIs have potential pharmacological, analgesic, and anticancer activities for the induction of cytotoxicity through apoptosis.

PPI, PPVI, and PPVII have been isolated from 13 *Paris* species, including *P. polyphylla* (ChongLou), *P. caobangensis*, *P. cronquistii*, *P. cronquistii* var. *xichouensis*, *P. delavayi* var. *petiolata*, *P. fargesii*, *P. mairei*, *P. polyphylla*, *P. polyphylla* var. *alba*, *P. polyphylla* var. *chinensis*, *P. polyphylla* var. *younanensis*, *P. vitenensis*, *P. axalis pseudothi*, and *P. polyphylla* var. *polyphylla*. These studies reported that the amount of isolated compounds from the same species of different regions varies possibly because of climate changes.

Among these PPIs, PPI has a significant therapeutic effect on hepatocellular carcinoma, lung adenocarcinoma, and gastric cancer. PPII has different pharmacological activities, including hemolytic effect and anticancer (e.g., against ovarian cancer). PPVI inhibits colon cancer by inducing apoptosis, PPVII is a potent compound for the treatment of cervical cancer by inhibiting the growth of Hela cells. PPD exerts a potent antiproliferative effect against different types of cancer cells, including HepG-2, MCF-7 and MDA-MB-231. These PPIs exhibit an anticancer effect against different cancers through different mechanisms. This review summarizes the anticancer mechanisms of these PPIs to provide basic knowledge for further studies.

**Non-Mechanistic Studies of PPIs in Different Cancers**

This section discusses those studies in which PP mechanisms are not reported. PPD inhibits the growth of HMEC-1 cells and decreases angiogenesis by suppressing cell proliferation, tube formation, and migration in vitro. PPD induces apoptosis in HL-60, SMMC-7721, A-549, MCF-7, and SW480 cell lines. PPD inhibits the proliferation of ovarian cancer (OVCA) cell lines, including KYKNU, M41-R, KYKNU-R, M41-R, PE01, A2780S, Skov3, OVCAR8, MCAS, A2780CP, HEYA8, and OVCAR5. In all cell lines, PPD treatment can significantly decrease cisplatin IC50. *Paris polyphylla* mixtures containing PPD inhibit the migration of LA795 cells in vitro and inhibit the tumor growth in vitro. PPVII induces death in different cell lines, including gastric cancer SNU-5, lung cancer A-549, skin cancer carcinoma A431, oral cancer OECM-1, breast MCF-7, pancreas MiaPaca-2, colon HTB-39, human normal fibroblasts (FR2).

**Mechanistic Studies of PPIs in Different Cancers**

This section discusses those studies in which PP mechanisms are reported.

**Apoptosis: PPIs Induce Apoptosis in Different Cancers Through the Following Mechanisms**

**Oxidative Stress**

Oxidative stress is the disturbance in redox signaling and regulation or physiological imbalance in the production of reactive oxygen species (ROS), such as oxygen (O2).
or hydrogen peroxide (H₂O₂), and the body’s ability to remove them.⁴⁹ ROS are generated throughout the body as by-products of cellular aerobic metabolism, exposure to X-rays or ultraviolet light, and on-going stress.⁵⁰ ROS play pivotal roles in cell signaling and the regulation of growth factors, transcription, cytokines, hormones, neuromodulation, apoptosis, and immunomodulation.⁵⁰,⁵¹ ROS also function in different cell processes, including cell survival, proliferation, differentiation, gene expression, elimination of pathogens or foreign particles, and enzyme regulation.⁵²,⁵³ The high oxidative stress in cancer cells increases cell survival, proliferation, angiogenesis, and metastasis; disrupts cell death signaling; and causes drug resistance.⁵⁴–⁵⁶ Although ROS increase cell proliferation, they have been recently deemed useful in cancer treatment. Plant-derived compounds induce apoptosis in cancer cells by promoting ROS generation in these cells above the threshold level.⁵⁴,⁵⁶–⁵⁸

Several PPs induce apoptosis in cancer cells through oxidative stress, which promotes the generation of ROS and the dissipation of mitochondrial membrane potential (MMP). In these PPs, PPI generates ROS and dissipates MMP in HCT 116 and MDA-MB-231 cells,⁵⁹–⁶¹ PPI in HepG2,⁶² PPVI in HepaRG,⁶³ PPG or PPVII in HepG-2 cells.⁶⁴ Furthermore, PPD or PSI and PPG or PPVII cause dissipation of MMP in K562/A02 human leukemia drug-resistant and K562 cells⁶⁵ and human NPC cells, respectively.⁶⁶ ROS generation and MMP dissipation are reversed by the ROS inhibitor N-acetyl-l-cysteine (NAC) treatment.⁶²–⁶⁴ Oxidative stress is further summarized in Figure 1A.

Mitochondrial-Dependent Pathway
The mitochondrial-dependent pathway is important for apoptosis induction, and any disturbance in this pathway prevents apoptosis. This pathway is regulated by B cell lymphoma-2 (Bcl-2) family proteins through changes in the permeability of the mitochondrial membrane for the release of different apoptotic proteins, including cytochrome-c (Cyt-c).⁶⁷ Anti-apoptotic proteins, such as B cell lymphoma extra-large (BclXL), Bcl-2, Bcl-2-related protein A1, and myeloid cell leukemia 1, increase cell survival. Pro-apoptotic proteins, including Bcl-2 homologous killer, Bcl-2 associated X (BAX), and Bcl-2 homology domain 3 (BH3)-only proteins act as receptor mediators and cause apoptosis by inducing mitochondrial stress.⁶⁸

BH3-only proteins have two subclasses: activators and depressors/sensitizers. Activators include total BH3 interacting domain death antagonist and Bcl-2 like protein-11. This subclass activates BAX/BAK directly and causes MMP depolarization. Depressor/sensitizers include Bcl-2-associated death promoter, Bcl-2-interacting killer, phorbol-12-myristate-13-acetate-induced protein-1, hara-kiri, and upregulated modulator of apoptosis p53. Instead of BAX/BAK activation, this subclass counterbalances anti-apoptotic proteins.⁶⁹,⁷⁰ Meanwhile, anti-apoptotic proteins block the death signaling pathway through the direct inhibition of activator BH3-only proteins or BAX/BAK activation.⁷¹ Anti-apoptotic proteins (Bcl-2 and Bcl-xl) cause cancer progression⁷² and therefore increase the resistance of tumor cells to different types of cell death stimuli, including anticancer drugs.⁷⁰

In hepatocarcinoma cells, PPI and formosanin C synergistically downregulate BCL2 inhibition and BAX upregulation and release of cytochrome from the mitochondria. Cytochrome c release from the mitochondria activates caspase-3,9 and induces hepatocarcinoma cell apoptosis.⁷³ In 143-B, MG-63, U-2 OS, non-small cell lung cancer (NSCLC), Saos-2, A549, SK-MES-1, H460, MDA-MB-231, MCF-7, U251, HepG-2, RPMI8226, SMC7721, and HO-8910M cells, PPI induces apoptosis through the mitochondrial-dependent pathway (MDP).⁷⁴–⁸³ In the MDP, PPI inhibits Bcl-2⁷⁴–⁷⁹ and BclxL⁷⁵ while activating Bax⁷⁴,⁷⁵,⁷⁸ and Bak,⁷⁵ triggering Cyt-c release from the mitochondria to the cytosol.⁶¹,⁷⁸,⁷⁹ The PPI-induced release of Cyt-c in the cytosol activates caspase-9⁶¹,⁷⁸,⁸³ caspase-3,⁷⁴–⁷⁷,80,8² and PARP.⁶¹,⁷⁴–⁷⁶,8⁰,8² The activated PARP enters the nucleus and causes DNA damage, leading to cell apoptosis.⁷⁷

PPI induces apoptosis in HepG2 cells through modulation of the mitochondrial pathway via downregulation of Bcl-2 and upregulation of Bax, triggering cytochrome c release from the mitochondria and caspase-9 activation. Activated caspase-9 further activates caspase-3 and PARP, respectively, resulting in apoptosis.⁶²

In MCF-7 and MDA-MB-231 cells, PPD induces mitochondrial-dependent apoptosis through MMP dissipation,⁷⁴ Bcl2 downregulation,⁷⁴ and Bax upregulation,⁷⁴ which further activate caspase-9,⁷⁴ leading to cell apoptosis.⁷⁴

In HepG2,⁷⁵ R-HepG2,⁷⁵ NB-69,⁸⁴ K562/A02,⁶⁵ U87 glioma,⁸⁵ SGC7901,⁸⁷ MCF-7,⁷⁴ MDA-MB-231,⁷⁴ and NSCLC cells, PPD or PSI induces apoptosis by modulating the mitochondrial-dependent pathway. In the mitochondrial-dependent pathway, PPD or PSI downregulates

---

Ahmad et al

OncoTargets and Therapy 2021:14

submit your manuscript | www.dovepress.com

DovePress

1823

---
Bcl2 and upregulates Bax. As a result, the mitochondrial membrane becomes permeable, and cytochrome c and AIF are released from the mitochondria to the cytosol, causing the activation of caspase-3, caspase-9, and PARP, leading to cell apoptosis. PPD-induced apoptosis was reversed by pretreatment with the inhibitor SP600125 through modulation of Bcl-2, Bax, caspase-3 and with the caspase inhibitor z-DEVD-fmk through downregulation of caspase-3 in HepG2 and R-HepG2 cells.

PPD or PSI also increases the apoptotic activity of other compounds, including camptothecin, 10-hydroxycamptothecin, cisplatin, and hyperthermia.

In H460, H446, and SGC-7901 cells, PSI sensitizes camptothecin-, 10-hydroxycamptothecin-, and cisplatin- induced apoptosis through modulation of the mitochondrial pathway. In the mitochondrial pathway, PSI inhibits Bcl2 and Bclxl while upregulating Bax and caspase-3 and causing mitochondrial membrane permeability and cytochrome-C release from the mitochondria into the cytosol.
PPVI in HepaRG cells induces MDP apoptosis through Bcl-2 downregulation and Bax upregulation, triggering cytochrome c release from the mitochondria and upregulating caspase-9 and PARP.\(^6\)

PPVII\(^6\) or PPG\(^6,91\) induces apoptosis in SAS,\(^91\) OEClM-1\(^92\), HepG-2,\(^6\) and NPC\(^6\) cells through downregulation of Bclx\(^96,91\) and Bcl2\(^6,4,91\) and upregulation of Bak,\(^91\) Bad,\(^6\) Bax,\(^6,66\) Bim,\(^91\) and tBid\(^91\) levels. This phenomenon causes cytochrome c\(^6\) release from the mitochondria to the cytosol, which further increases the cleavage of caspase-3\(^6,6,9,91\) and -9,\(^6,6,91\) z-VDAD-FMK (a broad-spectrum caspase inhibitor) was used in the following experiments to clarify the relevance of PPG-induced cell death. PG combined with Z-VDAD-FMK substantially increases the viability and decreases the apoptosis of HONE-1 and NPC-039 cells.\(^6\) Formosanin C and PPVII increase apoptosis in NCI-H460 cells by downregulating Bcl-2 and upregulating Bax, caspase-3, -8, and 9.\(^91\) The summarized form of the mitochondrial-dependent pathway is depicted in Figure 1A.

**Extrinsic Apoptotic Pathway**

Tumor-necrosis-factor (TNF) family proteins, such as Fas or TNF receptor (TNFR-1), activate the extrinsic apoptotic pathway.\(^93\) Fas or TNFR-1 upregulates caspase-8 through Fas-associated death domain, generating a death signaling complex that activates caspase-3 and results in cell death.\(^94,95\) In different cancers, NPs regulate the extrinsic apoptotic pathway.\(^96,97\)

PPVI induces the apoptosis of HepG2 cells by modulating the extrinsic apoptotic pathway via upregulation of FAS, caspase-8, and caspase-3.\(^6\) PPVI induces apoptosis in a dose-dependent manner in HepaRG,\(^6\) A549,\(^98\) and NCI-H1299\(^98\) cells by upregulating the expression of death receptor-3 (DR3),\(^98\) DR5,\(^98\) Fas,\(^98\) caspase-8,\(^6\) caspase-3,\(^6,98\) and cleaved PARP\(^6,98\) but downregulating the expression of decoy receptor-3 (Dr3),\(^98\) Pretreatment with Z-VDAD-FMK (caspase inhibitor) on HepaRG cells increases the percentage of viable cells, indicating that PPVI induces cell apoptosis through the mitochondrial pathway and the Fas death-dependent pathway.\(^6\) PPVII or PPG induces apoptosis in a dose-dependent manner in human NPC,\(^66\) A549,\(^98\) NCI-H1299,\(^98\) HepG2-2,\(^6,64\) SAS,\(^91\) and OEClM-1\(^92\) cells by upregulating the expression of DR3,\(^98\) DR5,\(^98\) Fas,\(^98\) caspase-8,\(^6,6,91\) cleaved PARP\(^98\) and cleaved caspase-3\(^6,6,91,98\) but downregulating the expression of Dr3.\(^98\) The summarized form of the extrinsic apoptotic pathway is depicted in Figure 1B.

**Signal Transducer and Activator of Transcription-3 Pathway**

Signal transducer and activator of transcription-3 (STAT3) regulates different cellular processes, including proliferation, differentiation, immune function, and survival.\(^99\) STAT3 is activated through its phosphorylation at tyrosine-705 (Y705) or serine-727 (S727).\(^100,101\) STAT3 can be activated by growth factor receptors, cytokine receptors, Janus kinases, sarcoma family kinases, and Abelson murine leukemia family kinases.\(^102,103\) STAT3 is expressed in different cancers\(^104,105\) and leads to transformation, resistance to chemotherapy, and tumorigenesis.\(^106\) These findings show that STAT3 is a good therapeutic target in the development of new drugs against cancer.

In NSCLC cells, the overexpression of IncRNA-metastasis-associated lung adenocarcinoma transcript-1 (MALAT1) increases STAT3 expression, which causes resistance to gefitinib, whereas PPI reverses the MALAT1-induced overexpression of STAT3 and causes cell apoptosis.\(^76\) Another study demonstrated that PPI reverses the IL6/STAT3-induced resistance to erlotinib in HCC827 cells.\(^108\) PP7- or PPVII-induced apoptosis in HepG2 cells by downregulating STAT3.\(^64\) The STAT3 pathway is further summarized in Figure 1C.

**Wnt/β-Catenin Pathway**

Wnt/β-catenin pathway is an oncogenic pathway that plays a crucial role in cancer progression.\(^108\) β-catenin is an intracellular signal transducer that plays an important role in cadherin protein complex and activates the Wnt/β-catenin pathway during embryonic development and tumorigenesis.\(^109-111\) Following activation of this pathway, wnt binds to membrane proteins, including serpentine receptors, frizzled family, and low-density lipoprotein receptor-related protein-5/6, which is necessary for disheveled (Dsh/Dvl) phosphorylation. Activated Dsh/Dvl works at intermediate and transfer signals from the Wnt/β-catenin-receptor complex to axis and glycogen-synthase-kinase -3β (GSK-3β) to downregulate the phosphorylation of β-catenin.\(^112-114\) As a result of Wnt binding to its receptors, the unphosphorylated β-catenin accumulates in the cytoplasm. The accumulated β-catenin enters the nucleus, where its downstream target genes, such as c-myc, are
activated. Furthermore, the Wnt-signaling pathway controls different cellular functions, including apoptosis, cell proliferation, migration, and invasion, which enhance the Wnt-dependent carcinogenesis. PPI inhibits cell growth, proliferation, and metastasis and induces apoptosis in 143-B, HOS, RPMI8226, and HO-8910M cells through the Wnt/β-catenin pathway. In the Wnt/β-catenin pathway, PPI inhibits Wnt5A and p-GSK-3β, further inhibiting β-catenin and its nuclear translocation. The PPI-reduced cell viability is abolished by GSK-3β specific inhibitor CHIR99021 while potentiated by β-catenin silencing. Furthermore, PPI inhibits the downstream regulator of β-catenin, such as survivin, as depicted in Figure 1D.

Cell Cycle
Cell cycle regulates cell growth at different checkpoints through the interaction of cyclin with exact cyclin-dependent kinases (CDKs), forming active complexes. The process ends before entering the new phase of the cell cycle. Then, CDKs are negatively regulated through different CDK inhibitors. CDK p21 controls the cell cycle at various checkpoints. Failed regulation of these checkpoints causes genomic rearrangement and mutation, resulting in genetic disturbance and ultimately cancer. Meanwhile, p53 is a key component that plays a crucial role in cell cycle regulation. A wide spectrum of damages and stresses activates p53. When p53 is activated through genotoxic stress, it controls the p21WAF1/CIP1/SD11 genes encoding CDKs universal inhibitors, resulting in cell cycle inhibition. A plethora of research demonstrated that the anticancer compound causes death in cancer cells through induction of cell cycle arrest.

In hepatocarcinoma, HCT 116, osteosarcoma 143-B, HOS, MG-63, U-2 OS, Saos-2, human myeloma RPMI8226, U266 cells, Du145, and PC3 cells, PPI causes cell cycle arrest in different phases, including G1, G2/M, S-phase, and G0/G1. In hepatocarcinoma cells, PPI and formosanin C synergistically upregulate p53, p21, and p27 and downregulate PCNA, CDK2, and Cyclin E, which lead to G1 phase cell cycle arrest. PPI in human myeloma RPMI8226 and U266 cells, U251 human glioma cells, HCT 116 cells 143-B and HOS cells induced ROS mediated G2/M phase cell cycle arrest through p21 upregulation which results in downregulations of cyclin B1, CD1 and c-myc. The ROS-mediated G2/M phase cell cycle arrest is reversed by NAC treatment. One study reported that PPI can cause S-phase cell cycle arrest in MG-63, U-2 OS, and Saos-2 osteosarcoma cells through downregulation of c-myc, Cyclin B1, Cyclin D1, and CDK1 time-dependently; this result suggests that the cell cycle arrest is due to cyclin/CD1 complex disturbance. Another study reported that PPI causes the G0/G1 phase cell cycle arrest in Du145 and PC3 cells with an unknown molecular mechanism.

PPD or PSI induces G2/M phase cell cycle arrest in SGC7901, NSCLC, K562, and K562/A02 through upregulation of CD145 and p21 and downregulation of cyclin B1, cyclin-dependent protein kinase, and Cdk1. PSI increases the cisplatin-induced G2/M phase cell cycle arrest in SGC-7901 cells through P21waf1/cip1 activation. PSI and hyperthermia at 43°C induce G2/M phase cell cycle arrest in NSCLC cell lines. PPII induces apoptosis and G2/M phase cell cycle arrest in a dose-dependent manner in A549 and NCI-H1299 cells by upregulating the expression P53 and p21 Waf1/Cip1, which may inhibit cyclin B1 in NCI-H1299 cells. PPVI induces S phase cell cycle arrest in HepaRG cells by decreasing the expression of cyclin A2 and CDK2 and upregulating the expression of p21.

In oral cancer OECM-1, SAS, NPC, A549, and NCI-H1299 cells, PPVI or PG induces cell cycle arrest at different stages, including G2/M, S-phase, and sub-G1 phase. PPVI induces G2/M phase cell cycle arrest by upregulating P53, p27, p21 Waf1/Cip1, Cdc25C, checkpoint kinase 1/2 (Chk1/2), and ataxia telangiectasia mutated and by downregulating cyclin B1 with no effect on p-Cdc21 (Tyr15). The G2/M phase cell cycle arrest due to p21and p27 has been confirmed through siRNA treatment. PPG or PPVII induces S-phase cell cycle arrest through the downregulation of Cyclin A and CDK2 expression in a dose-dependent manner. In addition, p21 and p27, inhibitors of the G1-to-S-promoting complex cyclin E-CDK2, significantly increase the protein level. However, the molecular mechanisms for sub-G1 phase cell cycle are unexplored. In gefitinib-sensitive PC-9 cells and acquired gefitinib-resistant H1975 cells, PPVII increases the sensitivity of gefitinib and induces G1 phase cell cycle arrest by upregulating p21 and downregulating CDK2, CDK4, Cyclin E, and Cyclin D1. The cell cycle is further summarized in Figure 2A–D.
Phosphatidyl-Inositol 3-Kinase/Protein Kinase-B/ Mammalian Target of Rapamycin Signaling Pathway

The phosphatidyl-inositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway promotes cell survival and growth through different molecular mechanisms. This pathway is activated in different types of cancer through multiple mechanisms. For example, AKT becomes activated as the phosphorylation of two residues including serine 473 (Ser 473) and threonine (Thr 308) of AKT occurs. After activation, AKT enters the nucleus, where it changes the activities of transcription regulating factor. PI3K/AKT signaling elevates mTOR expression, which is associated with poor prognosis. Different NPs cure cancer through inhibition of the PI3K/AKT/mTOR pathway.

PPI inhibits the proliferation and metastasis in ovarian cancer HO-8910M cells by downregulating PI3Kc2b. PP II increases the sensitivity of drug-resistant PC-9/ZD cells to gefitinib through the PI3K/Akt/mTOR pathway, in which it inhibits PI3K, AKT, and mTOR, which further activate Bax, caspase-9, and caspase-3 and trigger cell apoptosis. The PI3K/AKT/mTOR pathway is further summarized in Figure 3A.

Endoplasmic Reticulum Stress

The endoplasmic reticulum (ER) plays a role in the synthesis, signaling, and sensing of eukaryotic cells. In performing these functions, the ER must regulate oxidizing and the Ca⁡²⁺-rich folding environment. In the ER, Ca⁡²⁺ buffering
and protein folding are regulated by a number of chaperons, including calnexin, calreticulin, glucose-regulated protein GRP78 (BiP), and protein-disulfide isomerase. A number of pathophysiological conditions, including ER Ca^{2+} depletion, viral infection, hypoglycemia, oxidative injury, and hypoxia, affect the ER homeostasis and cause ER stress. The ER responds to these path-physiological changes by activating integrated signal transduction pathways through unfolded protein response (UPR).\textsuperscript{137} The UPR controls the ER homeostasis by activating ER folding machinery components, controlling ER quality, and coordinating gene transcription and ER-associated degradation (ERAD) pathway. When ER stress increases, the UPR changes from pro-survival to pro-death response, which leads to the activation of intrinsic apoptosis.\textsuperscript{138} Mammals have various ER stress transducers, including activating transcription factor 6 (ATF6), inositol requiring enzyme 1, and protein kinase RNA like endoplasmic reticulum (p-ERK). The UPR has pro-survival and pro-apoptotic responses; pro-survival response activates ER chaperons, translation attenuation, and ERAD, whereas pro-apoptotic response activates C/EBP homologous protein-10 (CHOP)/GADD153 and caspase-12.\textsuperscript{139}

PPI in MG-63, U-2 OS, and Saos-2 osteosarcoma cells dose-dependently activates the PERK branch of UPR, as determined by the increase in Bip expression, robust in eIF2α phosphorylation, and upregulation of ATF4 and GADD153 (CHOP) transcriptional factors.\textsuperscript{75}
PPD induces the ER stress in human NSCLC NCI-H460 cell line by upregulating glucose-regulated protein 78 (Bip/GRP78), protein disulfide isomerase (PDI), and C/EBP homologous transcription factor (chop), triggering cell apoptosis. The ER pathway is further summarized in Figure 3B.

**c-Jun N-Terminal Kinase Signaling Pathway**

The c-Jun N-terminal kinase (JNK) pathway regulates various physiological processes, such as cell differentiation, death, survival, inflammation, protein expression, and proliferation. Any failure in this pathway causes a spectrum of diseases, including cardiac hyper-therapy, diabetes, cancer, asthma, and auto-immune diseases. JNK plays a major role in oncogenic changes. The JNK pathways eliminate apoptosis by downregulating Ras transformation. Different NP s induce apoptosis in cancer cells by regulating the JNK pathway. In human glioma U251 and ovarian cancer HO-8910M cells, PPI induces apoptosis through the JNK pathway by upregulating JNK and c-Jun. Furthermore, PPI inhibits tumor growth by upregulating c-Jun. PPD induces apoptosis in U87 glioma cells by upregulating NH2-terminal kinase (JNK) phosphorylation, which is reversed by JNK inhibitor SP600125; this result suggests that the apoptosis is due to JNK pathway regulation. The JNK pathway is further summarized and depicted in Figure 3C.

**Nuclear Factor Kappa B Pathway**

The nuclear factor kappa B (NF-kB) pathway is a complex pathway consisting of five homo- and hetero-dimers of the reticuloendotheliosis oncogene cellular homolog (Rel) family, such as RelA (p-65), RelB, c-Rel, NF-kB1 (p-50/p-65), and NF-kB2 (p50/p65). In cancers, the NF-kB pathway becomes dysregulated. Active NF-kB has been reported in different cancers, including breast, prostate, colon, liver, leukemia, lymphoma, and ovarian cancer. As the DNA becomes damaged, the NF-kB pathway becomes activated, which results in the activation of NF-kB targeted genes, including Cyclo-oxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). These genes play pivotal roles in pro-survival anti-apoptosis. Therefore, NF-kB is a candidate for therapeutic resistance in different cancers. Different NPs have potential therapeutic efficacy against cancer by inhibiting NF-kB pathway activation in cancer cells.

PPI alone or in combination with formosanin C or cisplatin inhibits cancer through the NF-kB pathway in different cancer cell lines, including hepatocarcinoma cells, osteosarcoma 143-B, and HOS cells. In the NF-kB pathway, PPI alone or in combination downregulates NF-kB p-65 and IKBa. It also inhibits p65 translocation from the cytoplasm into the nucleus. Furthermore, this inhibition causes the downregulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP-9), leading to cell inhibition. One study demonstrated that the PPI in Du145 and PC3 cells inhibits NF-kB p65 in the cytoplasm, which further inhibits MUC1 expression and downregulates NF-kB p65 in the nucleus and HOT transcript antisense RNA (HOTAIR), which inhibits MUC1 expression and decreases Du145 and PC3 cell proliferation.

PPI inhibits the migration, invasion, and proliferation of PC3 and Du145 cells by inhibiting HOTAIR, which further inhibits DNA methyl-transferase 1 (DNMT1) and enhancer of zeste homolog 2 (EZH2) expression. Inhibition of EZH2 expression also inhibits cell proliferation. The NF-kB pathway is further summarized and illustrated in Figure 4A.

**Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated-Kinase Pathways**

The mitogen activated-protein kinase/extracellular signal-regulated kinase (MAPK/ERK) or Ras-Raf-MERK-ERK pathway possesses different cascades, but Ras-Raf-MERK-ERK 1 and 2 (ERK1/2) are mostly dysregulated in human cancer. This pathway regulates different cellular functions, including cell growth, differentiation, apoptosis, proliferation, migration, and senescence. The protein molecules of the MAPK/ERK pathway are activated through phosphorylation. Following activation, ERK enters the nucleus, where different transcription factors are activated. When these transcription factors are activated, they attach to the promoter region with different genes, including apoptosis inhibitory genes, cytokines, growth factors, and genes that increase cell proliferation. Dysregulation of this pathway causes drug resistance, tumorogenesis, and senescence, as detected in many human cancers. The MAPK pathway consists of ERK, JNK, and p38MAP kinase, which play a critical role in normal and cancerous cell proliferation and cause drug resistance. Small molecules targeting kinases in the MAPK pathway are not only useful in patients with NSCLC but also in patients with SCLC. NPs have a potential effect against cancer.
through MAPK pathways. Recently reported NPs, including PSI or PPD, PPVII or PPG have a potential antitumor effect through MAPK pathways.\textsuperscript{64,88,91}

PSI or PPD sensitizes the CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells and the suppression of AKT and ERK pathway activation in H460 cells.\textsuperscript{88}

PPVII or PPG induces apoptosis in HepG-2,\textsuperscript{64} OECM-1,\textsuperscript{92} and SAS\textsuperscript{91} cells by upregulating AKT,\textsuperscript{91} JNK,\textsuperscript{64,91} ERK,\textsuperscript{64,91} and p38.\textsuperscript{64,91} The involvement of the MAPK\textsuperscript{64,91} was evaluated using Akt inhibitor (LY294002),\textsuperscript{91} JNK inhibitor SP600125,\textsuperscript{64,91} ERK inhibitor PD98059,\textsuperscript{64,91} (5 μM), and p38 inhibitor SB203580\textsuperscript{64,91} to pre-treat HepG2,\textsuperscript{64} OECM-1,\textsuperscript{92} and SAS\textsuperscript{91} cells before the treatment of Pp7. The MAPK\textsuperscript{64} (AKT, ERK1/2, p38 and JNK1/2)\textsuperscript{91} inhibitors could significantly reduce the expression of apoptosis-related proteins in HepG2, OECM-1,\textsuperscript{91} and SAS\textsuperscript{91} cells and decrease the apoptosis\textsuperscript{64,91} and necrosis\textsuperscript{64} of HepG2 cells treated with pp7.\textsuperscript{64}

PPG-induced apoptosis in NPC cells through ERK1/2 and JNK1/2 and confirmed through the use of ERK1/2 inhibitor (U0126) increases the apoptosis and JNK1/2 inhibitor (SP600125), which inhibit the apoptosis caused by JNK upregulation.\textsuperscript{66} The PP anticancer effect through MAPK pathways is further summarized in Figure 4B.
AUTOPHAGY: PPs Induce Autophagy in Different Cancers Through the Following Mechanisms

PPs Induces Autophagy Through the PI3K/AKT/mTOR and AMPK/mTOR Pathways

A new target for cancer treatment is autophagy, which is activated through chemotherapy, nutrient deprivation, and oxidative stress and causes the degradation of damaged cytoplasmic organelles and proteins in response to external stress.\(^{165,166}\) Different signaling pathways are involved in autophagy, including adenosine mono-phosphate activated protein kinase (AMPK) and PI3K/AKT/mTOR pathways.\(^{167,168}\) The PI3K/AKT pathway serves as a positive regulator of the mTOR pathway and a negative regulator of autophagy in cancer cells\(^{169,11}\), but the disruption of PI3K/AKT/mTOR pathways through anticancer agents results in autophagy. AMPK regulates energy homeostasis and causes autophagy through inhibition of mTOR complex 1.\(^{168,170}\) Furthermore, the JNK pathway is involved in the autophagy of cancer cells in response to pharmacological stress.\(^{171,172}\) A number of studies revealed that autophagy is triggered by inhibition of the PI3K/AKT/mTOR pathway through a link with activation of the JNK pathway.\(^{173,174}\) Autophagy protein Beclin-1 interacts with Bcl-2, forms Beclin-1/Bcl-2 complex, and inhibits autophagy.\(^{175}\) Activated JNK causes Bcl-2 phosphorylation, results in Bcl-2 degradation, dissociates Beclin-1 from the Beclin-1/Bcl-2 complex, and causes autophagy.\(^{176-179}\) Furthermore, JNK activation is essential for anticancer agent-induced autophagy cell death.\(^{176,180}\)

One of the hallmarks of autophagy is the conversion of light chain 3I (LC3I) into its lipated form LC3II, which is essential for autophagosome formation in autophagy.\(^{181}\) Another marker of autophagic flux is P62, which has an inverse relation to autophagy activity. It binds to LC3 and degrades in autophagy.\(^{182}\) Moreover, in the study of autophagy, a commonly used approach is the examination of autophagic flux and autophagosome formation. A critical crosstalk between apoptosis and autophagy is Bcl-2, which inhibits autophagy through binding with Beclin-1 that initiates autophagosome formation during autophagy.\(^{175}\)

PP induces protective autophagy through the PI3K/AKT/mTOR pathway by inhibiting mTOR (S2448), AKT (S473), 70-kDa ribosomal protein S6 kinase (p70S6K (T389)), and 4E (eIF4E)-binding protein 1(4EBP1 (T37/46)) and increasing LC3I conversion into LC3II. In SMMC7721 and HepG2 cells, EGF markedly increases the phosphorylation of Akt and p70S6K and reverses LC3II, which suggests that the autophagy is due to the PI3K/AKT/mTOR pathway.\(^{182}\)

PP induces ROS-mediated autophagy in HCT 116 cells by inhibiting mTOR (s2448) and AKT (S473), p62 expression and increasing LC3II expression.\(^{59}\) The increase in LC3II is reversed by NAC pre-treatment.\(^{59}\)

PPVII or PPG treatment induces autophagy in HepG2,\(^{183}\) HONE-1, and NPC-039 cells via the PI3K/AKT/mTOR and AMPK/mTOR pathways. In the PI3K/AKT/mTOR pathway, PPVII inhibits the expression of PI3K,\(^{66,183}\) Akt\(^{183}\) and mTOR,\(^{66,183}\) activated mTOR (ser2448),\(^{66}\) total mTOR,\(^{66}\) Raptor,\(^{66}\) Rictor,\(^{66}\) and GβL\(^{66}\) in a dose-dependent manner.\(^{66,183}\) PPG-induced autophagic death is confirmed when Baf A1 and wortmannin (autophagy inhibitors) increase cell viability and PPG treatment alone exerts no effect on the apoptosis of HONE-1 and NPC-039 cells.\(^{66}\) PPVII also increases AMPK phosphorylation, which further inhibits mTOR and induces autophagy in HepG-2 cells through modulation of the AMPK/mTOR pathway.\(^{183}\) These mechanisms are further summarized in Figure 5.

PPs Induces Autophagy Through the Akt, p38MAPK, ERK1/2, and JNK Signaling Pathways

A new target for cancer treatment is autophagy, which is activated through chemotherapy, nutrient deprivation, and oxidative stress and causes the degradation of damaged cytoplasmic organelles and proteins in response to external stress.\(^{165,166}\) Previous research demonstrated that the AKT and MAPK pathways are involved in autophagy and apoptosis.\(^{172,184-186}\)

PPG or PPVII induces autophagy through the Akt, p38MAPK, ERK1/2, and JNK pathways in HepG-2,\(^{183}\) NPC-039,\(^{66}\) OECM-1,\(^{91}\) and SAS\(^{91}\) cells. PPG or PPVII activates JNK1/2\(^{66,91,183}\) and inhibits AKT,\(^{66}\) p38 MAPK,\(^{66}\) and ERK1/2,\(^{91}\) which further increases the conversion of LC3I to LC3II,\(^{66,183}\) P62 degradation,\(^{66,183}\) and formation of LC3-positive structures or LC3 puncta.\(^{66,183}\) Furthermore, PPVII treatment decreases total Bcl-2\(^{183}\) while increases p-Bcl-2\(^{183}\) and Beclin.\(^{66,183}\) The AKT inhibitor (LY294002)\(^{66}\) and JNK1/2 inhibitor (SP600125)\(^{66,183}\) decrease PPG-induced autophagy, whereas p38 MAPK inhibitor (SB203580)\(^{66}\) increases this process, suggesting that the PPG-induced autophagy is due to the Akt, p38 MAPK, and JNK1/2 pathways.\(^{66,183}\) Moreover, LY294002, U0126, and SP600125 significantly
attenuate PG-induced LC3-II activation, suggesting that the activation of ERK1/2 and JNK1/2 is involved in PG-induced autophagy. These mechanisms of autophagy are further summarized in Figure 5.

**Inflammation Pathway**

Inflammation is a physiological response for the protection of the body from tissue injury or infection and plays a critical role in different types of human cancers and other chronic diseases. In innate immune system, macrophages are the immune cells that play a central role in inflammation and protect the body from harmful stimuli. Active macrophages play important roles in host defenses against pathogens. They exert phagocytic activities and enhance inflammatory responses by producing different inflammatory factors, such as nitric oxide (NO) and prostaglandin-E2; proinflammatory mediators, such as iNOS, nitrogen species, metalloproteinases, and COX-2; and pro-inflammatory cytokines, such as TNF-α, interleukin-6 (IL-6), and IL-1β, which trigger other immune cells to the infection site. The overexpression of inflammation-related cytokines and mediators by activated macrophages is associated with the pathophysiology of different inflammatory and autoimmune
diseases. Lipopolysaccharide (LPS) is a potent macrophage activator and endotoxin derived from the cell wall of Gram-negative bacteria. When LPS stimulates the macrophages, the expression of cytokines and mediator is regulated by NF-kB through MAPKs, including JNKs, ERKs, and p38-MAPK. Macrophages secrete MMP-9, which controls leukocyte migration in inflammatory diseases. In macrophages, MMP-9 is regulated by LPS via the NF-kB and MAPK pathways. Therefore, targeting MAPKs, NF-kB, and MMP-9 through NPs may have a potential effect on the treatment of inflammatory diseases.

In RAW264.7 cells, PPVII inhibits the LPS-induced phosphorylation of p38, JNK, and ERK, which indicate the involvement of MAPKs in the suppression of cytokines and mediator by PPVII. Macrophage produces pro-inflammatory cytokines (major components of inflammation), including interleukin-6 (IL-6), IL-1β, and TNF-α, and the PPVII-inhibited productions of these cytokines are markedly increased in LPS-treated cells. Furthermore, PPVII inhibits IkB-α phosphorylation, increases the p65 level in the cytoplasm that is inhibited in the nucleus, and downregulates PGE-2, NO, iNOS, COX-2, and MMP-9 at the mRNA and protein levels in LPS-activated cells. The above discussion suggests that PPVII inhibits inflammation through the MAPK and NF-kB pathways, as illustrated in Figure 6A.

Necroptosis

Cell death usually occurs through two main pathways, namely, programmed cell death or apoptosis and direct cell damage or necrosis. Programmed necrosis or necroptosis is a new type of necrosis that has been recently reported. Necroptosis mechanisms involve the initial formation of a complex that contains receptor-interacting protein kinase-1 (RIPK1) induced by LPS and TNF. Furthermore, a complex is formed among RIPK3, RIPK1, Fas bound death domain protein, and caspase-8. By contrast, when the caspase-8 is inactive, RIPK3 and RIPK1 become activated and a RIP3 substrate known as mixed lineage kinase domain-like (MLKL) is phosphorylated, which attach to the cell membrane and form a hole in the cell membrane that causes the destruction of the cell membrane via necroptosis.

PPD-induced necroptosis in LA-N-2 and IMR-32 cells, which is confirmed when the cells are co-treated with nercosulfonamide (a specific inhibitor of RIPK3 associated with necroptosis), through inhibition of PPD-induced cell death, as illustrated in Figure 6B.

Mitophagy

Mitochondrial autophagy or mitophagy is a cellular pathway that helps in the removal of damaged mitochondria. Mitophagy plays a crucial role in the control of cancer microenvironment, cancer cell survival, and death. The study of molecular mechanisms of mitophagy might be important for the development of new cancer therapies. The PIKK1/PIK2 pathway regulates mitophagy. PARK-2 is a RING domain-containing E3 ubiquitin ligase, which is activated via autoubiquitination. In depolarized state, mitochondria use the uncoupling reagents, including carbonyl cyanide m-chlorophenyl-hydrazone (CCCP), and PARK2 enters the mitochondria and promotes its degradation. Furthermore, PARK2 overexpression induces the degradation of depolarized mitochondria via mitophagy. Given that PARK2 also selectively binds only to damaged mitochondria, it might help ensure the specificity of mitophagy. PTEN-induced kinase 1 (PINK1) has a targeting sequence located in the mitochondria. PINK1 protects the mitochondria from neurotoxin-induced injury, whereas loss of PINK1 function or mutation causes ROS-mediated mitochondrial injury. The full-length expression of PINK1 increases CCCP-mediated mitophagy or autophagy. Under stress conditions, the depolarization of mitochondrial membranes prevents the mitochondrial uptake and processing of PINK1; therefore, the unprocessed PINK1 on the outer membrane of the mitochondria recruits PARK2 and eliminates the damaged mitochondria through mitophagy. Dynamin-related protein 1 (DRP1) inhibitor mdivi-1 prevents mitophagy by inhibiting the fusion–fission cycle, which shows the importance of mitochondrial fission in mitophagy. The mitochondrial fission mediated by DRP-1 causes LC3B lipidation and mitophagy, for which PINK1 and PARK2 are required. A recent study has demonstrated that the LC3B-II autophagosome targets the mitochondrial membrane through interaction with C18-ceramide-LC3B-II, increases lethal mitophagy, and inhibits tumor growth. The above description demonstrates that mitophagy might be helpful in the identification of new therapies for cancer treatment.

In MDA-MB-231 cells, PPI induces DRP1 translocation to the mitochondria through dephosphorylation of DRP1 at ser-637, causing mitochondrial fission. PPI increases the stabilization of full-length PINK1 at the surface of mitochondria, leading to P62, PARK2, ubiquitin, and LC3B-II recruitment to the mitochondria and mitophagy. PPI-induced mitophagy is suppressed markedly with PINK1 knockdown. DRP1 suppression through...
shRNA or mdivi-1 inhibits the knockdown of PINK1 and PPI-induced mitochondrial fragmentation. These results suggest that PINK1 depletion leads to fission and mitochondrial fragmentation, as shown in Figure 6C.

**In vivo Anticancer Effect and Toxicity of PPs**

PPI inhibits tumor growth in lung cancer tumor xenograft and xenograft orthotopic mouse model without any side effects. PPI inhibits ovarian tumor in nude mice by downregulating Wnt5a, in PC-9-ZD xenograft by inhibiting MALAT1 and STAT3 expression, and in prostate cancer xenograft mouse model by inhibiting HOTAIR, DNMT1, and EZH2 expression. Furthermore, in MDA-MB-231 xenografts, PPI inhibits tumor growth that is enhanced by PINK1 knockdown. These findings show that PPI might be a good therapy for cancer. PPI inhibits the vasculogenic mimicry and microvessel density in PLC and PLC/Twist1 cells. Furthermore, immunohistochemically staining showed that PPI inhibits the expression of Twist1, VE-cadherin, vimentin, VEGFR1, and VEGFR2 and increases E-cadherin expression in tumor xenograft. PPI also overcomes the erlotinib resistance in HCC827-tumor.
xenografts by inhibiting IL-6; decreasing mesenchymal markers FN1, VIM, and SNAIL; and upregulating epithelial marker E-cadherin. In the embryo of zebrafish, PPD decreases the formation of inter-segmental vessels. PPD markedly inhibits the tumor in MCF-7 bearing nude mice with no obvious toxicity to heart and liver tissue nor increases the level of plasma enzymes, including aspartate transaminase, alanine transaminase, lactase dehydrogenase, and creatine kinase. PPD-containing saponins inhibit tumor growth in H22 tumor-bearing mice. In A549 xenografts, PPVI inhibits the tumor by causing apoptosis and G/M phase cell cycle arrest through upregulation of DR3, DR5, and p53 and attenuation of cyclin B1. PPVII and gefitinib inhibit tumor growth in acquiring gefitinib-resistant xenograft compared with either treatment alone. Furthermore, in xenograft model, PPVII and gefitinib activate the expression of p21 while reducing the expression of CDK4, CDK2, Cyclin D1, and Cyclin E compared with either treatment alone. In the NPC orthotopic graft model, PPG inhibits tumor growth by downregulating Ki67.

**In vivo Anti-Inflammatory Effect and Toxicity of PPs**

**In Mice**

PP7 dose-dependently suppresses the formation of xylene-induced ear edema in mice, suggesting that PP7 can potently inhibit acute inflammation in vivo. PP7 inhibits cotton pellet-induced granuloma formation in a dose-dependent manner in mice, indicating that it also inhibits chronic inflammation.

**In Zebrafish**

Zebrafish (Danio rerio) is a freshwater fish used as a vertebrate model organism for different inflammation studies because its acquired and innate immunity is highly similar to that of mammals. The transparency of zebrafish embryo and larva allows the dynamic and noninvasive imaging of in vivo inflammation. In adult zebrafish, the most abundant leukocytes are neutrophils; in BACmpx::GFP transgenic zebrafish, larvae possess green fluorescence in neutrophils, allowing the observation of neutrophil distribution in zebrafish. The numbers of neutrophils circulating near the lateral line neuromasts allow the measurement of inflammation. Copper sulfate and Lip+α-polysaccharide induce inflammation in zebrafish. PPVII strongly inhibits NO generation and decreases the heartbeat and the size of yolk sac edema in LPS-stimulated inflammation in zebrafish embryos. Furthermore, pre-treatment with PPVII reduces the recruitment of neutrophils to the injured area, suggesting the potential effect of PVII against inflammation.

**Conclusion**

PPs, including PPI, II, III, VI, VII, and PPD, are derived from different plants. These PPs exhibit potential effects against various cancers through different mechanisms in vitro and in vivo. PPs show their therapeutic effect on different cancers through apoptosis, autophagy, necroptosis, mitophagy, and inflammation. Among PPs, PPI targets apoptosis and autophagy through the PI3K/AKT/mTOR pathway. Thus, PPI is a candidate therapeutic drug for cancers activated by this pathway. In addition, although PPs target different pathways, a specific link among all pathways is lacking. Thus, researchers need to focus and find the link among these pathways. These PPs are ideal therapeutic drugs, and further research on their anticancer effect is highly encouraged.

**Acknowledgment**

The study was financially supported by the National Natural Science Foundation of China (81373875) and Liaoning Provincial Program for Top Discipline of Basic Medical Science (2012CB518803).

**Disclosure**

All authors declare that they have no competing interests in this work.

**References**

Ahmad et al


